Actinium to present Phase 1 ATNM-400 study at EANM 2026
The company announced an oral presentation highlighting its first-in-human Phase 1 study of ATNM-400, a non-PSMA-targeting radiotherapy in prostate cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.